



Generali Employee Benefits Network

#WeSpeakYourLanguage


Junho 2021



01

A nossa presença, a nossa visão

Construir juntos um futuro sustentável.



Generali Employee Benefits (GEB) Network

Inovação e Liderança – Informações consolidadas 2020




Uma única equipe por um serviço global

203 pessoas, 3 centros regionais e 12 escritórios



Proteger os seus valores, onde quer que estejam

Presente em 123 países à nível global, contando com os nossos 139 Seguradores Parceiros



■ Abrangência do GEB Network

Seguradores Parceiros

- ✓ seguradoras locais
- ✓ **com a melhor classificação** no seu mercado
- ✓ reconhecidas pelos seus **conhecimentos e serviços de alta qualidade**
- ✓ especialistas no setor dos benefícios à colaboradores.

A nossa missão: focados no caminho dos nossos Parceiros Vitalícios

Temos todos os elementos distintivos para ser um Parceiro de Vida



Um único ponto de contato,

por meio de nossas equipes dedicadas, oferecendo uma governança aprimorada e simplificação de processos



Uma abordagem global,

para garantir consistência e capacidade de resposta através da nossa extensa rede



Uma visão

técnica e inovadora, para identificar novas oportunidades e satisfazer as necessidades em evolução do cliente



Compartilhamento de dados e informações,


oferecendo serviços de alto valor agregado e um ecossistema de parcerias

Especialização em serviços à empresas multinacionais

02

As nossas soluções e serviços

Proteger os seus colaboradores, juntos.



As nossas soluções de benefícios para colaboradores

Tratamos do risco e a sua empresa reforça a governança.

Lifecycle Pooling

Global

É a solução para empresas multinacionais que desejam gerenciar com eficácia a estratégia geral de Benefícios para os Funcionários. O pool permite consolidar as coberturas de Benefícios de funcionários das filiais em todo o mundo em uma conta centralizada, com uma solução que se adapta ao tamanho e ao perfil de risco do Cliente e sua evolução ao longo do tempo.

Empresas Cativas

Global

Uma empresa cativa é uma resseguradora criada exclusivamente para segurar ou ressegurar os riscos do grupo ao qual pertence. Constitui uma abordagem estratégica à gestão dos planos de benefícios de seguros de uma empresa e oferece formas interessantes de gerir, financiar e disponibilizar pacotes de benefícios competitivos aos colaboradores com total transparência e controles.

Programa Subscrição Global

Global

Esta solução se baseia em uma estratégia de financiamento proactiva e inclui uma definição antecipada dos termos e das condições, melhorada e negociada a nível central, bem como taxas garantidas e otimização das variáveis de custos presentes em todo o programa com base em análises por país e cobertura.

Proteção local

Local

Trabalhamos em estreita colaboração com os nossos parceiros locais na escolha dos serviços e coberturas a oferecer às multinacionais e suas subsidiárias, beneficiando da sua experiência e capacidade de subscrição.


Serviços de saúde e bem-estar

Uma equipe dedicada, ferramentas digitais interativas e parcerias sólidas

Dashboard global de sinistros – planos médicos

Disponibiliza visões globais e específicas por país no que se refere a tendências e fatores que influenciam os custos.

Disponível para 40 países, cobrindo 90% da carteira GEB



Centro de Recursos de Saúde

Ferramentas online, serviços, pacotes de comunicação e parcerias para serviços digitais de saúde




Centro de dados do cliente

Clientes e corretores com acesso 24 horas por dia, 7 dias por semana, a dados, relatórios e dashboards

Um único ponto de acesso

- ✓ Painel online de dados históricos
- ✓ Atualizado trimestralmente
- ✓ Interativo
- ✓ Possibilidade de efetuar o download dos dados
- ✓ Âmbitos global, regional e local




Centro de Recursos COVID-19

Toda a informação disponível em geb.com/COVID-19.



- COVID-19 resources on GEB.com
- Updated on an ongoing basis
- Links to global health resources including WHO dynamic maps, public health sites
- Network partner T&Cs pertaining to Covid-19
- Region-specific detail including local health updates, ministry of health announcements, announcements from local hospital authorities



OUR CONTACTS & LOCATIONS

COVID-19

Being a General Partner to our clients is for us of the utmost importance and, today more than ever, it means building trust and going forward to overcome the emergency. With the outbreak of the Covid-19 epidemic, we have immediately taken action to make sure you are informed as to what we are doing as a Network for you and our employees.

This section is intended to be **informative and your practical advice** on COVID-19 **not for enable employees and multinational companies** at our the world.

GEB Network is highly committed to sharing updated information on local practices of managing COVID-19 outbreak and actively supporting insurance.

Find in the dedicated pages how GEB Network is responding to COVID-19 locally and which services are available for your employees.

For further questions, please contact info@geb.com
[View updated on the World Health Organization](#)

World Health Organization
WHO Regional Office for Europe
Data not current: 2020-05-20 13:29:03:07

194,917	5,704,736	357,736
new cases	confirmed cases	deaths

Globaly, as of 7:00pm CEST, 20 May 2020, there have been 5,704,736 confirmed cases of COVID-19, including 357,736 deaths, reported to WHO.

GEB Network supporting materials and useful links

- [Remove advice on COVID-19 for mobile employees - 08 May 2020](#) by [Euro Assistance](#)
Regular update on medical information and action recommendations regarding the COVID-19 outbreak.
- [Information and updates by the World Health Organization](#)
World Health Organization website dedicated to the COVID-19 outbreak with situation reports, travel advice, medical recommendations and an updated world map with the spread of COVID-19.
- [COVID-19 outbreak updates by Centers for Disease Control and Prevention](#)
Centers for Disease Control and Prevention website dedicated to the COVID-19 outbreak with useful tips on how to protect yourselves and to spot the symptoms. Recently used questions, travel advice and travel tips.



COVID-19 Health Bulletin

Keeping safe Simple steps for you and your family

Following is information drawn from public health sources on how to protect yourself and others from the COVID-19 virus.

Since there is no vaccine or drug therapy currently available, avoiding exposure and preventing spread are the best ways to keep everyone safe. Here are 6 steps you can take immediately to avoid exposure and prevent spread:

- 1** Maintain your social distance from others. If you have to go out for essential activities, keep at least 2 meters (approximately 6 feet) between yourself and others to prevent inhalation of droplets that can be shared by talking, sneezing or coughing.
- 2** Wash your hands with soap and water for at least 20 seconds. After this, use an alcohol-based hand sanitizer to continue to protect your hands from virus.
- 3** Avoid touching your eyes, nose, and mouth all of which are potential points of entry for the virus.
- 4** Practice good respiratory hygiene by coughing or sneezing into your bent elbow or a tissue; dispose of the tissue immediately in a sealed trash bin.
- 5** If you develop symptoms seek medical advice but call your doctor first. Calling your doctor or contacting a telemedicine provider if this is available to you will allow the health-care professional to direct you to an appropriate facility and help to prevent further spread of the virus.
- 6** Know when and how to wear a mask. Do wear a mask if you're coughing or sneezing, or if you're helping to care for someone who is sick.

Keep informed and up to date by following instructions and guidance from the WHO, the CDC, your local government and health authorities.

GENERALI
Employee Benefits Network

Source: <https://www.who.int/emergencies/diseases/novel-coronavirus-2019/clinical-guidance>

Boletim de vacinas contra a COVID-19

Saiba mais em geb.com/COVID-19.

Um informativo sobre as vacinas contra a COVID-19 atualizado mensalmente. Desenvolvido em colaboração com a Granite Management e contendo:

- ✓ Informações atualizadas sobre variantes do vírus
- ✓ Informações atualizadas sobre vacinas aprovadas ou em ensaios clínicos de Fase 3
- ✓ Impactos para os empregadores e quais as ações possíveis

COVID-19 Vaccine Update

February 2021

Continuing our research and product development, Generali Employee Benefits and Granite Management Limited (GML) have worked in collaboration to develop the latest summary offering presentation on available data related to COVID-19 vaccine development, and some suggested implications for global employers. We have also updated our previous offering presentation for more information on available COVID-19 vaccine development, and future plans. We have also updated our offering presentation for more information on available COVID-19 vaccine development, and future plans. We have also updated our offering presentation for more information on available COVID-19 vaccine development, and future plans.

February Updates

Growing threat of COVID variants

The variant appears to spread worldwide but is causing more illness than the original COVID-19 variant. It is spreading more rapidly and globally, causing increased illness and hospitalizations in a number of countries. It is also spreading more rapidly and globally, causing increased illness and hospitalizations in a number of countries.

There are concerns that this variant could spread only to be an illness against all the other variants. However, it also shows a lower rate of vaccine efficacy for certain and reduced its ability to be neutralized by antibodies. This variant is also spreading more rapidly and globally, causing increased illness and hospitalizations in a number of countries.

Emerging variants and notable mutations

Emerging variants are being monitored for their potential to spread more widely, cause more illness, and/or be more resistant to existing vaccines. Mutations are being monitored for their potential to spread more widely, cause more illness, and/or be more resistant to existing vaccines.

B.1.1.7 Variant (first identified in UK)

- Identified in 80 countries, associated to 30-50% of COVID-19 cases in the region. COVID-19 cases are spreading, but not clear if they are the 50% of cases from the original COVID-19 variant.
- Vaccine efficacy: There is a concern that this variant could spread only to be an illness against all the other variants. However, it also shows a lower rate of vaccine efficacy for certain and reduced its ability to be neutralized by antibodies. This variant is also spreading more rapidly and globally, causing increased illness and hospitalizations in a number of countries.

B.1.351 Variant (first identified in South Africa)

- Identified in 20 countries, likely to be the dominant variant in the region. COVID-19 cases are spreading, but not clear if they are the 50% of cases from the original COVID-19 variant.
- Vaccine efficacy: There is a concern that this variant could spread only to be an illness against all the other variants. However, it also shows a lower rate of vaccine efficacy for certain and reduced its ability to be neutralized by antibodies. This variant is also spreading more rapidly and globally, causing increased illness and hospitalizations in a number of countries.

P.1 Variant (first identified in Brazil)

- Identified in 12 countries and associated to 10-15% of COVID-19 cases in the region. COVID-19 cases are spreading, but not clear if they are the 50% of cases from the original COVID-19 variant.
- Vaccine efficacy: There is a concern that this variant could spread only to be an illness against all the other variants. However, it also shows a lower rate of vaccine efficacy for certain and reduced its ability to be neutralized by antibodies. This variant is also spreading more rapidly and globally, causing increased illness and hospitalizations in a number of countries.

Vaccine rollout across the globe

Vaccine rollout continues to proceed steadily across the globe. The rollout is expected to be completed by the end of the year. The rollout is expected to be completed by the end of the year.

% Population vaccinated by country


Country	Numbered	Percentage of population
USA	22.2%	22.2%
Spain	20.7%	20.7%
Germany	18.2%	18.2%
France	17.8%	17.8%
Italy	17.2%	17.2%
UK	16.8%	16.8%
Canada	16.2%	16.2%
Japan	15.8%	15.8%
China	15.2%	15.2%
India	14.8%	14.8%
South Korea	14.2%	14.2%
Italy	13.8%	13.8%
Spain	13.2%	13.2%
France	12.8%	12.8%
Germany	12.2%	12.2%
UK	11.8%	11.8%
Canada	11.2%	11.2%
Japan	10.8%	10.8%
China	10.2%	10.2%
India	9.8%	9.8%
South Korea	9.2%	9.2%
Italy	8.8%	8.8%
Spain	8.2%	8.2%
France	7.8%	7.8%
Germany	7.2%	7.2%
UK	6.8%	6.8%
Canada	6.2%	6.2%
Japan	5.8%	5.8%
China	5.2%	5.2%
India	4.8%	4.8%
South Korea	4.2%	4.2%
Italy	3.8%	3.8%
Spain	3.2%	3.2%
France	2.8%	2.8%
Germany	2.2%	2.2%
UK	1.8%	1.8%
Canada	1.2%	1.2%
Japan	0.8%	0.8%
China	0.2%	0.2%
India	0.1%	0.1%
South Korea	0.1%	0.1%
Italy	0.1%	0.1%
Spain	0.1%	0.1%
France	0.1%	0.1%
Germany	0.1%	0.1%
UK	0.1%	0.1%
Canada	0.1%	0.1%
Japan	0.1%	0.1%
China	0.1%	0.1%
India	0.1%	0.1%
South Korea	0.1%	0.1%
Italy	0.1%	0.1%
Spain	0.1%	0.1%
France	0.1%	0.1%
Germany	0.1%	0.1%
UK	0.1%	0.1%
Canada	0.1%	0.1%
Japan	0.1%	0.1%
China	0.1%	0.1%
India	0.1%	0.1%
South Korea	0.1%	0.1%
Italy	0.1%	0.1%
Spain	0.1%	0.1%
France	0.1%	0.1%
Germany	0.1%	0.1%
UK	0.1%	0.1%
Canada	0.1%	0.1%
Japan	0.1%	0.1%
China	0.1%	0.1%
India	0.1%	0.1%
South Korea	0.1%	0.1%
Italy	0.1%	0.1%
Spain	0.1%	0.1%
France	0.1%	0.1%
Germany	0.1%	0.1%
UK	0.1%	0.1%
Canada	0.1%	0.1%
Japan	0.1%	0.1%
China	0.1%	0.1%
India	0.1%	0.1%
South Korea	0.1%	0.1%
Italy	0.1%	0.1%
Spain	0.1%	0.1%
France	0.1%	0.1%
Germany	0.1%	0.1%
UK	0.1%	0.1%
Canada	0.1%	0.1%
Japan	0.1%	0.1%
China	0.1%	0.1%
India	0.1%	0.1%
South Korea	0.1%	0.1%
Italy	0.1%	0.1%
Spain	0.1%	0.1%
France	0.1%	0.1%
Germany	0.1%	0.1%
UK	0.1%	0.1%
Canada	0.1%	0.1%
Japan	0.1%	0.1%
China	0.1%	0.1%
India	0.1%	0.1%
South Korea	0.1%	0.1%
Italy	0.1%	0.1%
Spain	0.1%	0.1%
France	0.1%	0.1%
Germany	0.1%	0.1%
UK	0.1%	0.1%
Canada	0.1%	0.1%
Japan	0.1%	0.1%
China	0.1%	0.1%
India	0.1%	0.1%
South Korea	0.1%	0.1%
Italy	0.1%	0.1%
Spain	0.1%	0.1%
France	0.1%	0.1%
Germany	0.1%	0.1%
UK	0.1%	0.1%
Canada	0.1%	0.1%
Japan	0.1%	0.1%
China	0.1%	0.1%
India	0.1%	0.1%
South Korea	0.1%	0.1%
Italy	0.1%	0.1%
Spain	0.1%	0.1%
France	0.1%	0.1%
Germany	0.1%	0.1%
UK	0.1%	0.1%
Canada	0.1%	0.1%
Japan	0.1%	0.1%
China	0.1%	0.1%
India	0.1%	0.1%
South Korea	0.1%	0.1%
Italy	0.1%	0.1%
Spain	0.1%	0.1%
France	0.1%	0.1%
Germany	0.1%	0.1%
UK	0.1%	0.1%
Canada	0.1%	0.1%
Japan	0.1%	0.1%
China	0.1%	0.1%
India	0.1%	0.1%
South Korea	0.1%	0.1%
Italy	0.1%	0.1%
Spain	0.1%	0.1%
France	0.1%	0.1%
Germany	0.1%	0.1%
UK	0.1%	0.1%
Canada	0.1%	0.1%
Japan	0.1%	0.1%
China	0.1%	0.1%
India	0.1%	0.1%
South Korea	0.1%	0.1%
Italy	0.1%	0.1%
Spain	0.1%	0.1%
France	0.1%	0.1%
Germany	0.1%	0.1%
UK	0.1%	0.1%
Canada	0.1%	0.1%
Japan	0.1%	0.1%
China	0.1%	0.1%
India	0.1%	0.1%
South Korea	0.1%	0.1%
Italy	0.1%	0.1%
Spain	0.1%	0.1%
France	0.1%	0.1%
Germany	0.1%	0.1%
UK	0.1%	0.1%
Canada	0.1%	0.1%
Japan	0.1%	0.1%
China	0.1%	0.1%
India	0.1%	0.1%
South Korea	0.1%	0.1%
Italy	0.1%	0.1%
Spain	0.1%	0.1%
France	0.1%	0.1%
Germany	0.1%	0.1%
UK	0.1%	0.1%
Canada	0.1%	0.1%
Japan	0.1%	0.1%
China	0.1%	0.1%
India	0.1%	0.1%
South Korea	0.1%	0.1%
Italy	0.1%	0.1%
Spain	0.1%	0.1%
France	0.1%	0.1%
Germany	0.1%	0.1%
UK	0.1%	0.1%
Canada	0.1%	0.1%
Japan	0.1%	0.1%
China	0.1%	0.1%
India	0.1%	0.1%
South Korea	0.1%	0.1%
Italy	0.1%	0.1%
Spain	0.1%	0.1%
France	0.1%	0.1%
Germany	0.1%	0.1%
UK	0.1%	0.1%
Canada	0.1%	0.1%
Japan	0.1%	0.1%
China	0.1%	0.1%
India	0.1%	0.1%
South Korea	0.1%	0.1%
Italy	0.1%	0.1%
Spain	0.1%	0.1%
France	0.1%	0.1%
Germany	0.1%	0.1%
UK	0.1%	0.1%
Canada	0.1%	0.1%
Japan	0.1%	0.1%
China	0.1%	0.1%
India	0.1%	0.1%
South Korea	0.1%	0.1%
Italy	0.1%	0.1%
Spain	0.1%	0.1%
France	0.1%	0.1%
Germany	0.1%	0.1%
UK	0.1%	0.1%
Canada	0.1%	0.1%
Japan	0.1%	0.1%
China	0.1%	0.1%
India	0.1%	0.1%
South Korea	0.1%	0.1%
Italy	0.1%	0.1%
Spain	0.1%	0.1%
France	0.1%	0.1%
Germany	0.1%	0.1%
UK	0.1%	0.1%
Canada	0.1%	0.1%
Japan	0.1%	0.1%
China	0.1%	0.1%
India	0.1%	0.1%
South Korea	0.1%	0.1%
Italy	0.1%	0.1%
Spain	0.1%	0.1%
France	0.1%	0.1%
Germany	0.1%	0.1%
UK	0.1%	0.1%
Canada	0.1%	0.1%
Japan	0.1%	0.1%
China	0.1%	0.1%
India	0.1%	0.1%
South Korea	0.1%	0.1%
Italy	0.1%	0.1%
Spain	0.1%	0.1%
France	0.1%	0.1%
Germany	0.1%	0.1%
UK	0.1%	0.1%
Canada	0.1%	0.1%
Japan	0.1%	0.1%
China	0.1%	0.1%
India	0.1%	0.1%
South Korea	0.1%	0.1%
Italy	0.1%	0.1%
Spain	0.1%	0.1%
France	0.1%	0.1%
Germany	0.1%	0.1%
UK	0.1%	0.1%
Canada	0.1%	0.1%
Japan	0.1%	0.1%
China	0.1%	0.1%
India	0.1%	0.1%
South Korea	0.1%	0.1%
Italy	0.1%	0.1%
Spain	0.1%	0.1%
France	0.1%	0.1%
Germany	0.1%	0.1%
UK	0.1%	0.1%
Canada	0.1%	0.1%
Japan	0.1%	0.1%
China	0.1%	0.1%
India	0.1%	0.1%
South Korea	0.1%	0.1%
Italy	0.1%	0.1%
Spain	0.1%	0.1%
France	0.1%	0.1%
Germany	0.1%	0.1%
UK	0.1%	0.1%
Canada	0.1%	0.1%
Japan	0.1%	0.1%
China	0.1%	0.1%
India	0.1%	0.1%
South Korea	0.1%	0.1%
Italy	0.1%	0.1%
Spain	0.1%	0.1%
France	0.1%	0.1%
Germany	0.1%	0.1%
UK	0.1%	0.1%
Canada	0.1%	0.1%
Japan	0.1%	0.1%
China	0.1%	0.1%
India	0.1%	0.1%
South Korea	0.1%	0.1%
Italy	0.1%	0.1%
Spain	0.1%	0.1%
France	0.1%	0.1%
Germany	0.1%	0.1%
UK	0.1%	0.1%
Canada	0.1%	0.1%
Japan	0.1%	0.1%
China	0.1%	0.1%
India	0.1%	0.1%
South Korea	0.1%	0.1%
Italy	0.1%	0.1%
Spain	0.1%	0.1%
France	0.1%	0.1%
Germany	0.1%	0.1%
UK	0.1%	0.1%
Canada	0.1%	0.1%
Japan	0.1%	0.1%
China	0.1%	0.1%
India	0.1%	0.1%
South Korea	0.1%	0.1%
Italy	0.1%	0.1%
Spain	0.1%	0.1%
France	0.1%	0.1%
Germany	0.1%	0.1%
UK	0.1%	0.1%
Canada	0.1%	0.1%
Japan	0.1%	0.1%
China	0.1%	0.1%
India	0.1%	0.1%
South Korea	0.1%	0.1%
Italy	0.1%	0.1%
Spain	0.1%	0.1%
France	0.1%	0.1%
Germany	0.1%	0.1%
UK	0.1%	0.1%
Canada	0.1%	0.1%
Japan	0.1%	0.1%
China	0.1%	0.1%
India	0.1%	0.1%
South Korea	0.1%	0.1%
Italy	0.1%	0.1%
Spain	0.1%	0.1%
France	0.1%	0.1%
Germany	0.1%	0.1%
UK	0.1%	0.1%
Canada	0.1%	0.1%
Japan	0.1%	0.1%
China	0.1%	0.1%
India	0.1%	0.1%
South Korea	0.1%	0.1%
Italy	0.1%	0.1%
Spain	0.1%	0.1%
France	0.1%	0.1%
Germany	0.1%	0.1%
UK	0.1%	0.1%
Canada	0.1%	0.1%
Japan	0.1%	0.1%
China	0.1%	0.1%
India	0.1%	0.1%
South Korea	0.1%	0.1%
Italy	0.1%	0.1%
Spain	0.1%	0.1%
France	0.1%	0.1%
Germany	0.1%	0.1%
UK	0.1%	0.1%
Canada	0.1%	0.1%
Japan	0.1%	0.1%
China	0.1%	0.1%
India	0.1%	0.1%
South Korea	0.1%	0.1%
Italy	0.1%	0.1%
Spain	0.1%	0.1%
France	0.1%	0.1%
Germany	0.1%	0.1%
UK	0.1%	0.1%
Canada	0.1%	0.1%
Japan	0.1%	0.1%
China	0.1%	0.1%
India	0.1%	0.1%
South Korea	0.1%	0.1%
Italy	0.1%	0.1%
Spain	0.1%	0.1%
France	0.1%	0.1%
Germany	0.1%	0.1%
UK	0.1%	0.1%
Canada	0.1%	0.1%
Japan	0.1%	0.1%
China	0.1%	0.1%
India	0.1%	0.1%
South Korea	0.1%	0.1%
Italy	0.1%	0.1%
Spain	0.1%	0.1%
France	0.1%	0.1%
Germany	0.1%	0.1%
UK	0.1%	0.1%
Canada	0.1%	0.1%
Japan	0.1%	0.1%
China	0.1%	0.1%
India	0.1%	0.1%
South Korea	0.1%	0.1%
Italy	0.1%	0.1%
Spain	0.1%	0.1%
France	0.1%	0.1%
Germany	0.1%	0.1%
UK	0.1%	0.1%
Canada	0.1%	0.1%
Japan	0.1%	0.1%
China	0.1%	0.1%

Atualização trimestral sobre parceiros, soluções e serviços

Inscreva-se em geb.com para ter acesso a todas as novidades para os nossos Clientes e Corretores.



Temas



Vídeos



Artigos



Obrigado. Não vemos a hora de iniciar a nossa Viagem Juntos

Marketing & Customer Experience

Contacte-nos através do e-mail: MandCE@geb.com



Saiba mais em geb.com

#WeSpeakYourLanguage

Declaração de exoneração de responsabilidade

“Esta informação e comunicação são fornecidas pela Assicurazioni Generali S.p.A. – Filial do Luxemburgo (“a Empresa”), com sede social em 52, boulevard Marcel Cahen, L-1311 Luxemburgo, Grão-Ducado do Luxemburgo. Assicurazioni Generali SpA – Sucursal de Luxemburgo é a sucursal de Luxemburgo da Generali Assicurazioni S.p.A., uma sociedade de responsabilidade limitada nos termos da lei italiana, com sede social em 34132 Trieste, piazza Duca degli Abruzzi, 2, e constituída com o número de sociedade 00079760328. Ao usar esta Publicação, ou ao transferi-la, concorda com os Termos e Condições aqui estabelecidos e considerar-se-á que fica vinculado(a) aos mesmos.

O conteúdo desta Publicação é propriedade da Empresa. Todos os direitos são exclusivamente detidos pela Empresa. Nenhuma parte nem a totalidade do conteúdo desta Publicação podem ser copiadas, reproduzidas, transferidas, enviadas para sítios Web, publicadas ou distribuídas de qualquer forma sem a autorização prévia por escrito da Empresa, com a exceção de que a Empresa autoriza-o(a) a imprimir extratos destas páginas apenas para seu uso pessoal. As marcas comerciais e logótipos apresentados na presente Publicação são propriedade da Empresa e das suas subsidiárias (Grupo Generali) ou dos respetivos proprietários. Não podem ser usados sem o consentimento prévio por escrito da Empresa.

A informação constante na presente Publicação é fornecida de boa fé pela Empresa, que a considera ser precisa. A presente Publicação não pretende abranger todos os aspetos dos benefícios referidos e a Empresa não garante a sua integridade ou exatidão. A presente Publicação não foi elaborada para prestar aconselhamento jurídico ou de outro tipo e os leitores devem recorrer aos serviços de conselheiros jurídicos ou financeiros, inclusivamente no que se refere a benefícios internacionais. A informação constante na presente Publicação é produzida por fontes internas e externas. A Empresa reserva-se o direito de alterar a referida informação e as especificações funcionais e de utilização operacional aplicáveis à Publicação conforme e quando assim o entender, a seu critério e sem aviso prévio. A Empresa envidará todos os esforços para garantir que a informação apresentada na Publicação esteja em total conformidade com os requisitos de fiabilidade, veracidade e precisão. No entanto, a Empresa não se responsabiliza por quaisquer erros ou imprecisões no conteúdo da Publicação resultantes de circunstâncias que não possam ser atribuídas à Empresa. A Empresa não se responsabiliza pela fiabilidade, veracidade, exatidão e validade de qualquer informação constante na Publicação que não possa ser atribuída à Empresa. Além disso, a Empresa não aceita qualquer responsabilidade por quaisquer consequências adversas decorrentes de interrupções breves ou prolongadas, bem como de atrasos ou disfunções na prestação do serviço de Publicação, devido a circunstâncias fora do controlo da Empresa. Nenhuma parte da informação contida nos sítios Web para os quais são apresentadas hiperligações constitui uma recomendação, solicitação ou oferta, por parte da Empresa ou das suas afiliadas, de compra ou venda de quaisquer valores mobiliários ou outros instrumentos financeiros, e também não constitui qualquer aconselhamento ou serviço relativamente a investimento; parte da informação pode ser encontrada nos sítios Web para os quais são apresentadas hiperligações, na medida em que a sua publicação seja requerida ou recomendada por lei, por regulamentações ou por disposições de códigos de autorregulamentação. A informação constante na presente Publicação não pode ser utilizada, transferida para um dispositivo seu ou importada para o estrangeiro ou por estrangeiros em jurisdições onde a disposição, utilização, comunicação ou disseminação da mesma seja contrária a leis, regras ou regulamentações aplicáveis emanadas de qualquer autoridade governamental, organização regulamentadora, incluindo organizações de autorregulamentação ou em jurisdições onde a Empresa não esteja autorizada a fornecer tal informação ou tais serviços. Tal informação não constitui nem integra uma oferta realizada pela Empresa, ou em nome da Empresa, e também não constitui um convite à subscrição ou compra de quaisquer valores mobiliários em quaisquer países, incluindo quaisquer países estrangeiros e incluindo, sem limitação, os Estados Unidos da América ou qualquer “Pessoa dos EUA”, conforme definido no “Regulamento S” do United States Securities Act of 1933 [Lei de Valores Mobiliários dos Estados Unidos de 1933] (Lei de Valores Mobiliários), conforme posteriormente alterado, e não deve ser interpretada como tal.